Tech Company Financing Transactions
Alveron Pharma Funding Round
Alveron Pharma, based in Nijmegen, secured $5.3 million in funding from Broadview Ventures, Oost NL and Thuja Capital.
Transaction Overview
Company Name
Announced On
12/9/2024
Transaction Type
Venture Equity
Amount
$5,250,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage (ICH).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
NovioTech Campus Transistorweg 5
Nijmegen, 6534 AT
The Netherlands
Nijmegen, 6534 AT
The Netherlands
Phone
Undisclosed
Website
Email Address
Overview
Alveron Pharma is based in the Netherlands and UK and is backed by venture capital managers Thuja Capital (thujacapital.com) , Waterman Ventures (watermanventures.nl), Oost NL (oostnl.nl), Zwiers Pharma BV and Sanquin Innovatie BV. The company has also received an IK loan from the Dutch government. The drug OKL-1111 originates from a joint research project between OKKLO BV and Sanquin, the Dutch blood foundation. Alveron acquired the rights to OKL-1111 and is led by an experienced management team.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ben Nichols
Chief Operating Officer
Hash Patel
Chief Scientific Officer
Stephan Peters
VP - Bus. Development
Alex Zwiers
Browse more venture capital transactions:
Prev: 12/9/2024: Wanda Health venture capital transaction
Next: 12/9/2024: Element451 venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs